Flurbiprofen , ≥98.0%(HPLC) , 5104-49-4

Synonym(s):
(±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182;(±)-2-Fluoro-α-methyl-4-biphenylacetic acid;Flurbiprofen;Flurbiprofen - CAS 5104-49-4 - Calbiochem;L-790,330

CAS NO.：5104-49-4

Empirical Formula: C15H13FO2

Molecular Weight: 244.27

MDL number: MFCD00079303

EINECS: 225-827-6

PRODUCT Properties

• Melting point: 110-112 °C(lit.)
• Boiling point: 376.2±30.0 °C(Predicted)
• Density: 1.1795 (estimate)
• storage temp.: Sealed in dry,Room Temperature
• solubility: methanol: soluble50mg/mL
• pka: pKa 3.80(H2O) (Uncertain)
• form: White solid
• color: white to off-white
• Water Solubility: 8mg/L(room temperature)
• Merck: 14,4199
• InChIKey: SYTBZMRGLBWNTM-UHFFFAOYSA-N

Description and Uses

Flurbiprofen synthesis was originally reported in 1974. During a study of the pharmacological properties of a large number of substituted phenylalkanoic acids, including ibuprofen and ibufenac, the most potent were found to be substituted 2-(4-biphenyl)propionic acids. Further toxicological and pharmacological studies indicated that flurbiprofen possessed the most favorable therapeutic profile, so it was selected for further clinical development. It was not marketed until 1987, when it was introduced as the sodium salt as Ocufen, the first topical NSAID indicated for ophthalmic use in the United States. The indication for Ocufen is the same as that for Profenal—that is, to inhibit intraoperative miosis induced by prostaglandins in cataract surgery.

A cyclooxygenase inhibitor

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301
• Precautionary statements: P264-P270-P301+P310+P330-P405-P501
• Hazard Codes: T,C
• Risk Statements: 25-23/24/25
• Safety Statements: 36/37/39-45
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• RTECS: DU8341000
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 29163990